CDKN2A and gastric cancer: Further, in gastric cancer, as EBV-induced hypermethylation targets and silences key tumor suppressor genes including APC, RASSF1, BRCA1, THBS1, and CDKN2A, DNA methyltransferase inhibitors may also serve as a new therapeutic treatment for patients with EBV-positive gastric cancer (34, 129).